What does the Five Year Forward View mean for pharma?
December 6, 2016 | Five Year Forward View, STPs
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.
Introduction to the 5YFV
When it was launched in October 2014, the Five Year Forward View (5YFV) was hailed as one of the most radical changes in the management and organisation of NHS England since its inception in 1948. Designed by NHS England and five partner organisations, it aims to put an end to the age-old divide between GPs with patients, and consultants with hospitals, and develop new, integrated and cost efficient models of care that suit local needs. In doing so, it aspires to create a sustainable NHS that continues to be funded by the taxpayer, is free at the point of use and able to meet the evolving needs of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run, particularly at a local level. One of the biggest changes here is the planned introduction of STPs – Sustainability and Transformation Plans – in 2017, which will help to deliver 5YFV by providing blueprints for delivering services locally. Instead of taking a one-size fits all approach to healthcare provision, STPs will see the commissioner/provider split replaced by local planning and management within 44 areas across England called ‘footprints’. These area-specific, whole-system plans will identify the health needs of their populations and define how they should be addressed quickly and effectively at a local level. Understanding the bigger picture in terms of how STPs will affect areas such as NHS structure, leadership, commissioning, KPIs, efficiency, procurement and patient pathways is crucial for pharma. The industry also needs to get to grips with the priorities and primary objectives of the individual 44 STPs. Armed with this knowledge, the industry should look to offer tailored solutions that fit in with the aspirations of individual STPs and will help them to fulfil the needs of their local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key to accelerating the pace of change within the NHS and since October 2011, NHiS, which is part of Wilmington Healthcare, has been helping to do this through its Mental Health Commissioning Network conferences. The events, which are being sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded people together to discuss and exchange ideas on how to treat people with mental health problems in a more integrated way. Wherever possible, they involve locally identified Chairs plus the Strategic Clinical Networks, Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma companies to get involved in shaping patient pathways and improving NHS services in line with the objectives of 5YFV.
Conclusion
Since its inception in 2014, 5YFV has been dramatically changing the way that NHS services are run, particularly at local level, and further major changes will occur when STPs are introduced next year. In the midst of this upheaval, there are golden opportunities for pharma to get involved in redesigning NHS services. The key is to keep abreast of the changes, understand the bigger picture and find ways to utilise its expertise to add value.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Wilmington Healthcare appoints new Head of Digital
Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.In his new role,...
How has the pandemic reshaped the NHS in 2020?
Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset
How can pharma align its brand strategy with the NHS Reset?
Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era
Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs
White paper helps industry navigate new NHS roadmap
New report shows how pharma can support the NHS in the Covid-19 recovery era
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home
Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it